197 related articles for article (PubMed ID: 19684609)
1. Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway.
Cao LQ; Wang XL; Wang Q; Xue P; Jiao XY; Peng HP; Lu HW; Zheng Q; Chen XL; Huang XH; Fu XH; Chen JS
Acta Pharmacol Sin; 2009 Sep; 30(9):1316-22. PubMed ID: 19684609
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B.
Cao LQ; Shao ZL; Peng HP; Xiao JB; Xia T
Chin J Cancer; 2010 Aug; 29(8):741-6. PubMed ID: 20663321
[TBL] [Abstract][Full Text] [Related]
3. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.
Shen B; Chu ES; Zhao G; Man K; Wu CW; Cheng JT; Li G; Nie Y; Lo CM; Teoh N; Farrell GC; Sung JJ; Yu J
Br J Cancer; 2012 Apr; 106(9):1486-94. PubMed ID: 22472882
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells.
Cao LQ; Chen XL; Wang Q; Huang XH; Zhen MC; Zhang LJ; Li W; Bi J
Acta Pharmacol Sin; 2007 Jun; 28(6):879-87. PubMed ID: 17506947
[TBL] [Abstract][Full Text] [Related]
5. PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404.
Zhang W; Wu N; Li Z; Wang L; Jin J; Zha XL
Cancer Biol Ther; 2006 Aug; 5(8):1008-14. PubMed ID: 16775433
[TBL] [Abstract][Full Text] [Related]
6. The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression.
Zhou S; Ye W; Duan X; Zhang M; Wang J
Dig Dis Sci; 2013 Jun; 58(6):1615-26. PubMed ID: 23314856
[TBL] [Abstract][Full Text] [Related]
7. Dioscin suppresses hepatocellular carcinoma tumor growth by inducing apoptosis and regulation of TP53, BAX, BCL2 and cleaved CASP3.
Zhang G; Zeng X; Zhang R; Liu J; Zhang W; Zhao Y; Zhang X; Wu Z; Tan Y; Wu Y; Du B
Phytomedicine; 2016 Nov; 23(12):1329-1336. PubMed ID: 27765352
[TBL] [Abstract][Full Text] [Related]
8. Hydrazinocurcumin and 5-fluorouracil enhance apoptosis and restrain tumorigenicity of HepG2 cells via disrupting the PTEN-mediated PI3K/Akt signaling pathway.
Zhou Y; Zhang M; Zhang Z; Jia Y; Zhang C; Peng L
Biomed Pharmacother; 2020 Sep; 129():109851. PubMed ID: 32559627
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma.
Zhang YQ; Tang XQ; Sun L; Dong L; Qin Y; Liu HQ; Xia H; Cao JG
World J Gastroenterol; 2007 Mar; 13(10):1534-40. PubMed ID: 17461445
[TBL] [Abstract][Full Text] [Related]
10. TFPI-2 downregulates multidrug resistance protein in 5-FU-resistant human hepatocellular carcinoma BEL-7402/5-FU cells.
Lu F; Hou YQ; Song Y; Yuan ZJ
Anat Rec (Hoboken); 2013 Jan; 296(1):56-63. PubMed ID: 23125179
[TBL] [Abstract][Full Text] [Related]
11. Combined effect of honokiol and rosiglitazone on cell growth inhibition through enhanced G0/G1 phase arrest in hepatoma cells.
Chen HC; Hsu HT; Weng JW; Chang YF; Hsia CY; Lee HC; Chi CW
J Chin Med Assoc; 2016 Aug; 79(8):415-21. PubMed ID: 27094504
[TBL] [Abstract][Full Text] [Related]
12. Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells.
Gu W; Liu L; Fang FF; Huang F; Cheng BB; Li B
Oncol Rep; 2014 Jan; 31(1):216-22. PubMed ID: 24173654
[TBL] [Abstract][Full Text] [Related]
13. MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells.
Ke M; Dong J; Wang Y; Zhang J; Zhang M; Wu Z; Lv Y; Wu R
Int J Biochem Cell Biol; 2018 Aug; 101():39-48. PubMed ID: 29800725
[TBL] [Abstract][Full Text] [Related]
14. Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone.
Teresi RE; Shaiu CW; Chen CS; Chatterjee VK; Waite KA; Eng C
Int J Cancer; 2006 May; 118(10):2390-8. PubMed ID: 16425225
[TBL] [Abstract][Full Text] [Related]
15. Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression.
Cao LQ; Shao ZL; Liang HH; Zhang DW; Yang XW; Jiang XF; Xue P
Cancer Lett; 2015 Apr; 359(1):127-35. PubMed ID: 25592041
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of anti-tumor effects of 5-fluorouracil on hepatocellular carcinoma by low-intensity ultrasound.
Hu Z; Lv G; Li Y; Li E; Li H; Zhou Q; Yang B; Cao W
J Exp Clin Cancer Res; 2016 Apr; 35():71. PubMed ID: 27102814
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug‑resistant human hepatocellular carcinoma cells to 5‑FU.
Tang B; Hu Z; Li Y; Yuan S; Wang Z; Yu S; He S
Mol Med Rep; 2016 Jan; 13(1):59-66. PubMed ID: 26549838
[TBL] [Abstract][Full Text] [Related]
18. The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.
Shim J; Kim BH; Kim YI; Kim KY; Hwangbo Y; Jang JY; Dong SH; Kim HJ; Chang YW; Chang R
Int J Oncol; 2010 Jan; 36(1):223-31. PubMed ID: 19956851
[TBL] [Abstract][Full Text] [Related]
19. CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth.
Cheung KF; Zhao J; Hao Y; Li X; Lowe AW; Cheng AS; Sung JJ; Yu J
Cancer; 2013 Mar; 119(6):1217-26. PubMed ID: 23212831
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
